The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial
Open accessAbstract
Background: Hepatitis C virus (HCV) infection is common in persons who inject drugs (PWID). Objective: To evaluate elbasvir-grazoprevir in treating HCV infection in PWID. Design: Randomized, placebo-controlled, double-blind trial. (ClinicalTrials.gov: NCT02105688). Setting: Australia, Canada, France, Germany, Israel, the Netherlands, New Zealand, Norway, Spain, Taiwan, the United Kingdom, and the United States. Patients: 301 treatment-naive patients with chronic HCV genotype 1, 4, or 6 infection who were at least 80% adherent to visits for opioid agonist therapy (OAT). Intervention: The immediate-treatment group (ITG) received elbasvir-grazoprevir for 12 weeks; the deferred-treatment group (DTG) received placebo for 12 weeks, no treatment for 4 weeks, then open-label elbasvir-grazoprevir for 12 weeks. Measurements: The primary outcome was sustained virologic response at 12 weeks (SVR12), evaluated separately in the ITG and DTG. Other outcomes included SVR24, viral recurrence or reinfection, and adverse events. Results: The SVR12 was 91.5% (95% CI, 86.8% to 95.0%) in the ITG and 89.5% (95% CI, 81.5% to 94.8%) in the active phase of the DTG. Drug use at baseline and during treatment did not affect SVR12 or adherence to HCV therapy. Among 18 patients with posttreatment viral recurrence through 24-week follow-up, 6 had probable reinfection. If the probable reinfections were assumed to be responses, SVR12 was 94.0% (CI, 89.8% to 96.9%) in the ITG. One patient in the ITG (1 of 201) and 1 in the placebo-phase DTG (1 of 100) discontinued treatment because of an adverse event. Limitation: These findings may not be generalizable to PWID who are not receiving OAT, nor do they apply to persons with genotype 3 infection, a common strain in PWID. Conclusion: Patients with HCV infection who were receiving OAT and treated with elbasvir-grazoprevir had high rates of SVR12, regardless of ongoing drug use. These results support the removal of drug use as a barrier to interferon-free HCV treatment for patients receiving OAT. Primary Funding Source: Merck & Co.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
Self-citationNelson, P. K., Mathers, B. M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., & Degenhardt, L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61097-0 · Cited by 1,267
Comparative analysis of two rates
Miettinen, O., & Nurminen, M. (1985) · Statistics in Medicine · doi:10.1002/sim.4780040211 · Cited by 1,110
Epidemiology and natural history of HCV infection
Hajarizadeh, B., Grebely, J., & Dore, G. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.107 · Cited by 994
Self-citationZeuzem, S., Ghalib, R., Reddy, K. R., Pockros, P. J., Ari, Z. B., Zhao, Y., Brown, D. D., Wan, S., DiNubile, M. J., Nguyen, B.-Y., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0785 · Cited by 516
Self-citationBarua, S., Greenwald, R., Grebely, J., Dore, G. J., Swan, T., & Taylor, L. E. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0406 · Cited by 401
Self-citationAspinall, E. J., Corson, S., Doyle, J. S., Grebely, J., Hutchinson, S. J., Dore, G. J., Goldberg, D. J., & Hellard, M. E. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit306 · Cited by 309
Self-citationRockstroh, J. K., Nelson, M., Katlama, C., Lalezari, J., Mallolas, J., Bloch, M., Matthews, G. V., Saag, M. S., Zamor, P. J., Orkin, C., et al. (2015) · The Lancet HIV · doi:10.1016/s2352-3018(15)00114-9 · Cited by 305
Self-citationLawitz, E., Gane, E., Pearlman, B., Tam, E., Ghesquiere, W., Guyader, D., Alric, L., Bronowicki, J.-P., Lester, L., Sievert, W., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61795-5 · Cited by 299
Self-citationSulkowski, M., Hezode, C., Gerstoft, J., Vierling, J. M., Mallolas, J., Pol, S., Kugelmas, M., Murillo, A., Weis, N., Nahass, R., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61793-1 · Cited by 280
Self-citationSumma, V., Ludmerer, S. W., McCauley, J. A., Fandozzi, C., Burlein, C., Claudio, G., Coleman, P. J., DiMuzio, J. M., Ferrara, M., Di Filippo, M., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00324-12 · Cited by 259
Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
Sulkowski, M. S., Naggie, S., Lalezari, J., Fessel, W. J., Mounzer, K., Shuhart, M., Luetkemeyer, A. F., Asmuth, D., Gaggar, A., Ni, L., et al. (2014) · JAMA · doi:10.1001/jama.2014.7734 · Cited by 254
Self-citationSerti, E., Chepa-Lotrea, X., Kim, Y. J., Keane, M., Fryzek, N., Liang, T. J., Ghany, M., & Rehermann, B. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.004 · Cited by 245
Restoration of HCV-specific CD8+ T cell function by interferon-free therapy
Martin, B., Hennecke, N., Lohmann, V., Kayser, A., Neumann-Haefelin, C., Kukolj, G., Böcher, W.-O., & Thimme, R. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.05.043 · Cited by 223
Cost–Effectiveness of Hepatitis C Virus Antiviral Treatment for Injection Drug User Populations
Martin, N. K., Vickerman, P., Miners, A., Foster, G. R., Hutchinson, S. J., Goldberg, D. J., & Hickman, M. (2012) · Hepatology · doi:10.1002/hep.24656 · Cited by 221
Discovery of MK‐8742: An HCV NS5A Inhibitor with Broad Genotype Activity
Coburn, C. A., Meinke, P. T., Chang, W., Fandozzi, C. M., Graham, D. J., Hu, B., Huang, Q., Kargman, S., Kozlowski, J., Liu, R., et al. (2013) · ChemMedChem · doi:10.1002/cmdc.201300343 · Cited by 201
Recommendations for the management of hepatitis C virus infection among people who inject drugs
Grebely, J., Robaeys, G., Bruggmann, P., Aghemo, A., Backmund, M., Bruneau, J., Byrne, J., Dalgard, O., Feld, J. J., Hellard, M., et al. (2015) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.07.005 · Cited by 194
Self-citation
Cited by
EASL recommendations on treatment of hepatitis C: Final update of the series☆
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.018 · Cited by 1,252
Self-citationGhany, M. G., Morgan, T. R., & Panel, A. H. C. G. (2020) · Hepatology · doi:10.1002/hep.31060 · Cited by 955
Metadata
- Authors
- Dore, G. J., Altice, F., Litwin, A. H., Dalgard, O., Gane, E. J., Shibolet, O., Luetkemeyer, A., Nahass, R., Peng, C.-Y., Conway, B., Grebely, J., Howe, A. Y. M., Gendrano, I. N., Chen, E., Huang, H.-C., Dutko, F. J., Nickle, D. C., Nguyen, B.-Y., Wahl, J., Barr, E., Robertson, M. N., Platt, H. L., & on behalf of the C-EDGE CO-STAR Study Group
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-08-09
- Volume
- 165
- Issue
- 9
- Pages
- 625
- ISSN
- 0003-4819 (ISSN-L)
- OpenAlex
- W2518041763
- Cited by
- 359
- References
- 19
- FWCI
- 39.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.